Merck Rotavirus Vaccine Has Low Risk Of Intussusception, FDA Review Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Discrepancies in reports of follow-up time prevent the agency from reaching a conclusion on RotaTeq’s efficacy.
You may also be interested in...
Merck's RotaTeq Safety Data Is Reassuring, FDA Vaccine Committee Says
FDA's Vaccines & Related Biological Products Advisory Committee votes unanimously that Merck's data indicate the rotavirus vaccine is safe.
Merck's RotaTeq Safety Data Is Reassuring, FDA Vaccine Committee Says
FDA's Vaccines & Related Biological Products Advisory Committee votes unanimously that Merck's data indicate the rotavirus vaccine is safe.
RotaShield Return? Biovirx Plans Global Reintroduction Of Vaccine
Biovirx obtained a global license from NIH; the firm will seek a partner for the U.S. and Europe. Wyeth withdrew the rotavirus vaccine in July 1999 due to an increased risk of intussusception in vaccinated infants.